FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- Study type
- Clinical guideline
- Study name
- EANM FDG PET/CT v2.0
- Design
- Procedure guideline (clinical and technical guidance) of the European Association of Nuclear Medicine (EANM)
- Source
- Eur J Nucl Med Mol Imaging · 2014
In plain words
This document guides imaging centres on performing and reporting FDG PET/CT scans in a standard way. Standardisation makes the result of a patient's scan more comparable and more reliable across different centres and scanners. This matters for diagnosis, staging and assessing how a tumour responds to treatment.
Key guideline recommendations
To maintain the accuracy and precision of quantification in PET, a common quality control (QC) and quality assurance (QA) procedure is required.
Imaging biomarkers should have adequate repeatability (the same result in the same patient on the same scanner) and reproducibility (the same result across different scanners and centres).
The guidelines specifically aim to achieve harmonisation of standardised uptake values (SUV) in multicentre settings.
Study population
Adult patients referred for oncological FDG PET/CT imaging.
Endpoints
This document is a procedure guideline and has no clinical endpoint. Its aim is to help physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT and in achieving harmonisation of standardised uptake values (SUV) across multiple centres.
Safety and side effects
The abstract gives no information on adverse events.
Clinical significance and place in guidelines
This guideline provides a common technical and quality control framework for performing and interpreting FDG PET/CT in oncology so that SUV values are more harmonised across centres and multicentre trials. The abstract does not explain approvals or its place in other clinical guidelines, and this should be checked separately.
Limitations
The abstract does not include technical details of the procedures (such as patient preparation, injected radiopharmaceutical activity, scan timing and quality control criteria) or the level of evidence of the recommendations; these should be checked in the full text of the guideline.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.